Tim Johnson, Ph.D. Email & Phone Number

Cambridge, Massachusetts, United States

Cambridge, Massachusetts, United States

- Established and operationalized the New Product Planning & Competitive Intelligence functions covering the oncology/hematology portfolio. Demonstrated functional value led to rapid, company-wide integration and strategic shifts in our development programs.- Market forecasts supported $465M Lengo Therapeutics acquisition and $1.25B strategic financing round - Appointed to Chief of Staff of the Portfolio Management Team to support portfolio prioritization and governance of development to commercial-stage programs.- Requested to support Blueprint’s 2022 Investor Day event with 200+ invited investors.- Led company-wide ED&I speaker event to increase disease and racial/health disparity understanding while inspiring employees on the global impact of their work.

Cambridge, Massachusetts, United States

Greater Boston Area

New product planning for Bioverativ’s cell therapy programs in beta-Thalassemia and Sickle Cell Disease- Developed the corporate business case, commercial forecasts, and pre/post-launch operational framework, along with identifying key opportunities to expand the market and disease targets. - Led a cross-functional team to define the target product profile and strategic considerations.- Evaluated market opportunities for a variety of rare hematologic and genetic diseases.Interim Head of Program Managemento Identified organizational gaps, recruited, and hired key program & project managers.

Led the global commercial launch activities for Sanofi Genzyme's pipeline therapeutic that aims to treat the non-neurological manifestations of ASMD (acid sphingomyelinase deficiency)

Supported the head of the Global Rare Hematology business unit. Particularly focused on driving the prioritization for additional rare hematological diseases to the portfolio, providing commercial input for the development of a therapeutic for Gaucher Disease Type 3, and developing statistical long-range demand forecasts for the performance of commercial products.

Hematology Business Unit Strategic Development - Self‐initiated a collaboration with the head of Genzyme’s hematology business unit to refine and further develop a vision for the Gaucher franchise. - Developed a global differential pricing scheme that is locally responsible while maintaining profitability. Technical & Organizational Leadership - Led the technical development of Genzyme’s disruptive biomanufacturing platform: a design for the continuous and universal production of protein therapeutics that significantly reduces operational and capital costs while flexibly able to meet multiproduct and variable market demands. - Interim co‐director of 24 person cell culture development department during director’s departure.

- Led the team that increased enzyme production >80‐fold over current commercial production rates. - Developed the vision and led the efforts to improve organizational strength which resulted in increased communication, accountability, and career planning, while reducing employee turnover from 21% to 4%

Held multiple leadership roles in support of Cerezyme commercial production. Led the discovery that increased bioreactor productivity >2‐fold while leading a multidisciplinary team to stabilize near‐term commercial production rates.

Doctor Of Philosophy (Phd), Chemical Engineering

Bachelor'S Degree, Chemical Engineering